Navigation Links
FDA Approves Human Hookworm Vaccine for Phase I Safety Trials

At first, we thought that gene expression was modulated only by transcription factors. Then we found that the RNA resulting from transcription could be regulated by the RISC complex (siRNA-mediated degradation via Dicer). And now it seems that regulation at the RNA level is even more complex than we first imaginated...

As any dedicated video game player knows, the first requirement for using a weapon or tool is finding it. And it is no different for cell biologists and clinicians who want to take control of gene expression in cells to create therapies to treat disease. While cells have a variety of ways to control gene expression, the trick for players in this game is to recognize them amidst the incredibly complex background of cellular machinery.

Now, in a paper in the January 28th issue of Cell, Lynne E. Maquat, Ph.D., professor of Biochemistry and Biophysics at the University of Rochester Medical Center, and her team have identified a novel pathway for RNA degradation, a form of regulation that has garnered significant attention in recent years, and one that has the potential to produce a new set of tools for physicians to use to fight disease.

Most of the gene-control tools researchers have collected thus far involve the first step in gene expression, in which DNA is copied into RNA transcripts. However, recent discoveries have shown that many of the tools cells use to regulate genes work after transcription, by moderating the activity and the life span of the RNA itself.

One major pathway for such post-transcriptional regulation is called nonsense-mediated decay (NMD). Originally NMD was thought to destroy incorrectly transcribed or otherwise problematic RNAs, but investigators now know that it plays a major role in regulating the life span of numerous RNAs, and thus controls gene activity.

To better understand what controls the NMD system, Maquat and her postdoctoral fellow, Yoon Ki Kim, Ph.D., used a critical c omponent of the NMD complex, Upf1, as bait in a molecular fishing expedition. With this approach, proteins that naturally interact with the bait will be pulled out of the pool of cellular proteins.

They found that Upf1 grabbed onto Staufen1 (Stau1). Stau1 is a well-known RNA binding protein and some of its functions in the common fruit fly Drosophila are understood. "But no one knew what Staufen1 did in human cells," said Maquat, even though its presence in mammalian cells has been recognized for several years.

"We were surprised to find that Staufen1 interacts with Upf1," she added. "This is a whole new function for Staufen1 that couldn't have been predicted from the studies in flies, even though a similar function may occur in flies."

The team discovered that Staufen1 doesn't interact with other components of the NMD complex ?and altering the amount of Staufen1 in the cell didn't change NMD function. Those observations, said Maquat, sent Kim on a hunt for what Staufen1 and Upf1 were doing.

Looking at gene expression data available through the lab of Luc DesGroseillers, Ph.D. at the University of Montreal, they found that Staufen1 protein binds to numerous RNAs. Downregulating the amount of Staufen or Upf1 increased the half-life of these RNAs. Significantly, altering the amount of another NMD factor didn't affect these RNAs.

Thus, Staufen1 and Upf1, together, degrade RNAs by a previously undescribed mechanism, which the team called Staufen1-mediated degradation (SMD). Preliminary results suggest that SMD activity affects numerous transcripts and, therefore, is a novel mechanism of gene regulation.

"We don't yet understand how SMD is regulated but it must be," said Maquat. "Both Upf1 and Staufen1 can be phosphorylated, so their activities could be regulated by cell signaling pathways, such as those mediated by changes in growth conditions." That would allow the cell to differentially control the level of SMD-target RN As, while leaving the NMD-regulated RNAs untouched.

This is likely to be the "tip of the iceberg" for Staufen1's function in mammalian cells, said Maquat, and just the beginning of the SMD story as well.


'"/>

Source:


Related biology news :

1. FDA Approves New Drug to Treat Type I and Type II Diabetes
2. FDA Approves New Treatment for Chronic Hepatitis B
3. New Clues Add 40,000 Years to Age of Human Species
4. Human Cells Filmed Instantly Messaging for First Time
5. Govt Creates Gene Database of Normal Human Tissues
6. Analysis Of Human Genome To Predict The Development Of Illnesses
7. Human Eggs Can Develop From Ovarian Surface Cells In Vitro
8. Determining The Fate Of Cells In The Human Body
9. Whole genome promoter mapping - Human Genome Project v2.0?
10. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
11. Going To Extremes To Improve Human Health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology: